share_log

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A:其他
美股SEC公告 ·  11/06 16:27

Moomoo AI 已提取核心信息

On November 6, 2024, bluebird bio, Inc., a biotechnology company focused on gene therapies, announced the partial adjournment of its annual stockholders' meeting to solicit additional votes for Proposal 4, which involves a reverse stock split. The meeting, which took place on the same day, saw the approval of Proposals 1, 2, 5, 6, and 7, while Proposal 3 was not approved. The adjourned meeting is scheduled to reconvene on December 4, 2024, to address Proposal 4 exclusively. This proposal seeks to amend the company's certificate of incorporation to allow a reverse stock split at a ratio between 1-for-15 and 1-for-20, as determined by the board of directors. CEO Andrew Obenshain cited the risk of delisting from Nasdaq due to the current stock price and the need for additional capital to...Show More
On November 6, 2024, bluebird bio, Inc., a biotechnology company focused on gene therapies, announced the partial adjournment of its annual stockholders' meeting to solicit additional votes for Proposal 4, which involves a reverse stock split. The meeting, which took place on the same day, saw the approval of Proposals 1, 2, 5, 6, and 7, while Proposal 3 was not approved. The adjourned meeting is scheduled to reconvene on December 4, 2024, to address Proposal 4 exclusively. This proposal seeks to amend the company's certificate of incorporation to allow a reverse stock split at a ratio between 1-for-15 and 1-for-20, as determined by the board of directors. CEO Andrew Obenshain cited the risk of delisting from Nasdaq due to the current stock price and the need for additional capital to reach cash flow breakeven in the latter half of the next year. The board strongly encourages stockholders to vote in favor of the reverse stock split, which has received support from proxy advisory firms ISS and Glass Lewis. The company also announced a conference call to discuss third quarter 2024 results on November 14, 2024.
2024年11月6日,专注于基因疗法的生物技术公司蓝鸟生物宣布部分休会其年度股东大会,以征求有关提案4的额外投票,该提案涉及股票的逆向拆分。在同一天举行的会议中,提案1、2、5、6和7获得批准,而提案3未获批准。休会的会议定于2024年12月4日重新召开,专门讨论提案4。此提案旨在修正公司的公司章程,允许以董事会确定的比率(1股拆为15至1股拆为20)进行股票的逆向拆分。首席执行官安德鲁·奥本山因当前股价面临纳斯达克退市风险以及2025年下半年达到盈利盈亏平衡所需的额外资本而发表了此番言论。董事会强烈建议股东投票支持逆向股票拆分,该提案已获得代理咨询公司ISS和Glass Lewis的支持。该公司还宣布于2024年11月14日召开电话会议,讨论2024年第三季度的财报。
2024年11月6日,专注于基因疗法的生物技术公司蓝鸟生物宣布部分休会其年度股东大会,以征求有关提案4的额外投票,该提案涉及股票的逆向拆分。在同一天举行的会议中,提案1、2、5、6和7获得批准,而提案3未获批准。休会的会议定于2024年12月4日重新召开,专门讨论提案4。此提案旨在修正公司的公司章程,允许以董事会确定的比率(1股拆为15至1股拆为20)进行股票的逆向拆分。首席执行官安德鲁·奥本山因当前股价面临纳斯达克退市风险以及2025年下半年达到盈利盈亏平衡所需的额外资本而发表了此番言论。董事会强烈建议股东投票支持逆向股票拆分,该提案已获得代理咨询公司ISS和Glass Lewis的支持。该公司还宣布于2024年11月14日召开电话会议,讨论2024年第三季度的财报。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息